TrialBlood cancer journal2019

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.

Binod Dhakal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.